Actively Recruiting
Phase II Evaluation of HF1K16 Combined With Bevacizumab for Adults With Recurrent or Progressive Glioma
Led by HighField Biopharmaceuticals Corporation · Updated on 2026-07-10
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the combination of HF1K16 and Bevacizumab in adults with recurrent or progressive glioma to evaluate its preliminary anti-tumor effects and safety. This Phase II, multicenter, open-label study focuses on reversing immune suppression in the tumor environment and inhibiting blood vessel growth to enhance treatment impact. The study is sponsored by HighField Biopharmaceuticals Corporation. Participants receive combination therapy involving HF1K16, which contains all-trans retinoic acid and targets immune cells, given via intravenous infusion on specified days within a 28-day cycle, alongside Bevacizumab. The study includes a dose-escalation phase with three planned dose levels of HF1K16, followed by an adaptive expansion phase to further evaluate efficacy and safety. Throughout the study, participants will be monitored for side effects, progression-free survival, and overall survival for up to two years. Assessments include tracking adverse events, tumor response, immune cell changes, and other clinical outcomes. Participants must meet specific health and laboratory criteria and will be followed closely to evaluate treatment tolerability and disease control.
CONDITIONS
Brief Title
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
Research Team
X
xun Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
